Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules In Vivo

Human Gene Therapy

Volumn 13, Issue 4, 2002, Pages 569-575

  Oertli, Daniel ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a   Marti, Walter R ^a   Zajac, Paul ^a   Noppen, Christoph ^a   Kocher, Thomas ^a   Padovan, Elisabetta ^a   Adamina, Michel ^a   Schumacher, Reto ^a   Harder, Felix ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; MELAN A; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; NONAPEPTIDE; PSORALEN; RECOMBINANT VACCINE; TUMOR ANTIGEN; VIRUS VECTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNIZATION; MELANOMA; NONHUMAN; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; MELANOMA; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 0036202012     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340252809856     Document Type: Article

References (46)

1. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immunosurveillance in metastatic lesions
2. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
3. B70 antigen a second ligand for CTLA-4 and CD28
4. Transporter associated with antigen processing-independent presentation of endogenously synthesized peptides is enhanced by endoplasmatic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide
5. Colorectal cancer vaccines: Antiidiotypic antibody, recombinant protein, and viral vector
6. Stringent allele/epitope requirements of MART-1/Melan A immunodominance: Implications for peptide-based immunotherapy
7. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer
8. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
9. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells
10. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
11. Structure of vaccinia virus early promoters
12. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein
13. A shift in the phenotype of Melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
14. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
15. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
16. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
17. Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor
18. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
19. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1
20. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
21. The pattern of cytokine gene expression in freshly excised human meta-static melanoma suggests a state of reversible anergy of tumor infiltrating lymphocytes
22. Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
23. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
24. + T lymphocytes in vitro
25. An HLA-A2 polyepitope vaccine for melanoma immunotherapy
26. Frequency of cytotoxic T lymphocyte precursors in interacting with autologous tumor via the T-cell receptor
27. Cellular immune responses to HIV
28. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD81 T cells in melanoma patients receiving interleukin 12
29. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
30. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
31. Vaccinia as a vector for tumor-directed gene therapy: Biodis-tribution of a thymidine kinase-deleted mutant
32. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity
33. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
34. Recombinant vaccinia encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer
35. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
36. + melanoma patients by mature monocyte-derived dendritic cells
37. A cell culture model for T lymphocyte clonal anergy
38. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
39. Gene expression and cytopathic effect of chemically inactivated vaccinia virus
40. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
41. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
42. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
43. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding Mart-1/Melan-A 27-35 epitope
44. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules
45. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine